Iovance Biotherapeutics (IOVA) Cash from Financing Activities (2010 - 2026)

Iovance Biotherapeutics (IOVA) has reported Cash from Financing Activities for 15 consecutive years, with $94.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 34.18% year-over-year to $94.3 million; the TTM figure through Mar 2026 stood at $251.8 million (down 26.03% YoY), while the FY2025 annual figure was $300.8 million, down 23.01% from the prior year.
• Cash from Financing Activities improved to $94.3 million in Q1 2026 per IOVA's latest filing, from $56.2 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $258.2 million in Q1 2023 and bottomed at -$2.1 million in Q2 2022.
• Historically, Cash from Financing Activities has averaged $84.6 million across 5 years, with a median of $56.2 million in 2025.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 101.26% — and 2023, when it soared 90033.33%.
• Iovance Biotherapeutics' Cash from Financing Activities stood at $190.6 million in 2022, then tumbled by 99.5% to $962000.0 in 2023, then jumped by 140.02% to $2.3 million in 2024, then soared by 2332.74% to $56.2 million in 2025, then jumped by 67.94% to $94.3 million in 2026.
• Business Quant data shows IOVA's Cash from Financing Activities at $94.3 million in Q1 2026, $56.2 million in Q4 2025, and $88.1 million in Q3 2025.